COMMUNIQUÉS West-GlobeNewswire
-
Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product
26/02/2026 -
Highridge Medical Begins a Limited Launch of the activL® Lumbar Disc with Strong Early Surgeon Adoption
26/02/2026 -
Femasys Announces FemBloc® Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access
26/02/2026 -
PROCEPT BioRobotics® Hosts 2026 Investor Day to Detail Multi-year Financial Outlook and Strategic Plan for Long-Term Growth
26/02/2026 -
Iovance Biotherapeutics to Present at Upcoming Conferences
26/02/2026 -
SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247
26/02/2026 -
FibroBiologics to Present at the BIO Investment & Growth Summit
26/02/2026 -
OneMedNet Partners with ViuHealth to Enhance Autoimmune Dataset Scale, Accelerating Recurring Revenue from Life Sciences and AI Customers
26/02/2026 -
U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma’s Patent 11,697,028 To Be Unpatentable
26/02/2026 -
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus
26/02/2026 -
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2025 Financial Results
26/02/2026 -
Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy
26/02/2026 -
InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference
26/02/2026 -
Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026
26/02/2026 -
Cronos Group Reports 2025 Fourth Quarter and Full-Year Results
26/02/2026 -
Glow Holdings, Inc. Launches New Corporate Website
26/02/2026 -
NETHERTON NOW Recognizes Rare Disease Day and Highlights Growing Global Awareness of Netherton Syndrome
26/02/2026 -
PharmAla Signs Drug Donation Agreement for MDMA-Assisted Therapy Clinical Trial in Fibromyalgia
26/02/2026 -
Yoolie Park joins Solésence, Inc. as Vice President of Brand Partnerships
26/02/2026
Pages